Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehaa276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zinc-lysine and iron-lysine mitigate chromium toxicity in pearl millet (Pennisetum glaucum) through modulating photosynthetic and antioxidant system and inhibiting chromium uptake and translocation.
Environ Sci Pollut Res Int
December 2024
Department of Agronomy, Faculty of Agricultural Sciences, SGT University, Gurugram, India.
Chromium (Cr) is an ever-present abiotic stress that negatively affects crop cultivation and production worldwide. High rhizospheric Cr concentrations inhibit nutrients uptake and their translocation to aboveground parts, thus can affect the growth and development of crop plants. This experiment was designed to evaluate the effects of sole and combined zinc-lysine and iron-lysine applications on photosynthetic efficacy, antioxidative defense, oxidative stress, and nutrient uptake and translocation under Cr stress.
View Article and Find Full Text PDFThe effect of biosynthesized zinc oxide nanoparticles on gene expression and apoptosis in triple-negative breast cancer cells.
Daru
December 2024
Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Objective(s): Some forms of breast cancer such as triple-negative phenotype, are serious challenge because of high metastatic cases, high mortality and resistance to conventional therapy motivated the search for alternative treatment approaches. Nanomaterials are promising candidates and suitable alternatives for improving tumor and cancer cell treatments.
Materials And Methods: Biosynthesis of ZnO NPs by help of Berberis integerrima fruit extract, has been done.
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
J Med Chem
December 2024
Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Rearranged during transfection (RET) kinase is a validated therapeutic target for various cancers characterized by RET alterations. Although two selective RET inhibitors, selpercatinib and pralsetinib, have been approved by the FDA, acquired resistance through solvent-front mutations has been identified rapidly. Developing proteolysis targeting chimera (PROTAC) targeting RET mutations offers a promising strategy to combat drug resistance.
View Article and Find Full Text PDFNovel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents.
J Med Chem
December 2024
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, , a dual-target inhibitor for PD-L1 and VISTA is identified.
View Article and Find Full Text PDFAccuracy of Preliminary Maxillary Canine and Anchorage Tooth Movement in Premolar Extraction Cases Using 12 In-House Clear Aligners: A Randomised Control Trial Comparing Power Arm and Control.
Orthod Craniofac Res
December 2024
Department of Orthodontics, Faculty of Dentistry, Mahidol University, Bangkok, Thailand.
Objectives: To investigate maxillary canine movement accuracy and anchorage during space closure in first premolar extraction cases (maximum anchorage) using In-House Clear Aligners (IHCAs).
Materials And Methods: A randomised controlled trial with a split-mouth design recruited 16 adults in university setting. Each patient was randomly assigned by side for canine retraction using 12 IHCAs to both the experimental palatal power arm (Pa) and non-Pa control (C).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!